Belde KASAP DEMİR, Demet ALAYGUT, Caner ALPARSLAN, Eren SOYALTIN, Fatma MUTLUBAŞ, Seçil ARSLANSOYU ÇAMLAR, Önder YAVAŞCAN, Merve ARYA, Afig BERDELİ

Demographic and clinical characteristics of children with autosomal dominant polycystic kidney disease: a single center experience

Background/aim: In children with autosomal dominant polycystic kidney disease (ADPKD), clinical manifestations range from severe neonatal presentation to renal cysts found by chance. We aimed to evaluate demographic, clinical, laboratory findings, and genetic analysis of children with ADPKD. Materials and methods: We evaluated children diagnosed with ADPKD between January 2006 and January 2019. The diagnosis was established by family history, ultrasound findings, and/or genetic analysis. The demographic, clinical, and laboratory findings were evaluated retrospectively. Patients

PDF

___

1. Reddy BV, Chapman AB. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatric Nephrology 2017;32 (1): 31-42. doi: 10.1007/s00467-016- 3364-y
2. De Rechter S, Breysem L, Mekahli D. Is autosomal dominant polycystic kidney disease becoming a pediatric disorder? Frontiers in Pediatrics 2017; 5: 272. doi: 10.3389/ fped.2017.00272
3. Fırıncı F, Soylu A, Kasap Demir B, Turkmen M, Kavukcu S. An 11-year-old child with autosomal dominant polycystic kidney disease who presented with nephrolithiasis. Case Reports in Medicine 2012: 428749. doi: 10.1155/2012/428749
4. Cachat F, Combescure C, Cauderay M, Girardin E, Chehade H. A systematic review of glomerular hyperfiltration assessment and definition in the medical literature. Clinical Journal of the American Society of Nephrology 2015; 10 (3): 382-389. doi: 10.2215/CJN.03080314
5. Gabow PA. Autosomal dominant polycystic kidney disease. New England Journal of Medicine 1993; 329 (5): 332-342. doi: 10.1056/NEJM199307293290508
6. Reed B, McFann K, Kimberling WJ, Pei Y, Gabow PA et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. American Journal of Kidney Diseases 2008; 52 (6): 1042-1050. doi: 10.1053/j.ajkd.2008.05.015
7. Dudley J, Winyard P, Marlais M, Cuthell O, Harris T et al. Clinical practice guideline monitoring children and young people with, or at risk of developing autosomal dominant polycystic kidney disease (ADPKD). BMC Nephrology 2019; 20 (1): 148. doi: 10.1186/s12882-019-1285-2
8. Golin CO, Johnson AM, Fick G, Gabow PA. Insurance for autosomal dominant polycystic kidney disease patients prior to end-stage renal disease. American Journal of Kidney Diseases 1996; 27 (2): 220-223. doi: 10.1016/s0272- 6386(96)90544-2
9. Simms RJ, Thong KM, Dworschak GC, Ong AC. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation 2016; 31 (7): 1130-1140. doi: 10.1093/ndt/gfv299
10. Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney International 2015; 88 (1): 17-27. doi: 10.1038/ki.2015.59
11. Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation 2016; 31 (3): 337-348. doi: 10.1093/ ndt/gfv456
12. Gilbert RD, Evans H, Olalekan K, Nagra A, Haq MR et al. Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease. Pediatric Nephrology 2017; 32 (5): 893-896. doi: 10.1007/s00467-017-3584-9
13. Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA et al. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. European Journal of Pediatrics 2019; 178 (7): 1013-1021. doi: 10.1007/s00431-019- 03384-x
14. Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology 2014; 9 (5): 889-896. 10.2215/CJN.08350813
15. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Prospective change in renal volume and function in children with ADPKD. Clinical Journal of the American Society of Nephrology 2009; 4 (4): 820-829. doi: 10.2215/ CJN.02810608
16. De Rechter S, Bammens B, Schaefer F, Liebau MC, Mekahli D. Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective. Clinical Journal Kidney 2018; 11 (Suppl. 1): i14-i26. doi: 10.1093/ckj/sfy088
17. Marlais M, Cuthell O, Langan D, Dudley J, Sinha MD et al. Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis. Archives of Disease in Childhood 2016; 101 (12): 1142-1147. doi: 10.1136/archdischild-2015-310221
18. Helal I, Reed B, McFann K, Yan XD, Fick-Brosnahan GM et al. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology 2011; 6 (10): 2439-2443. doi: 10.2215/CJN.01010211
19. Flahault A, Trystram D, Nataf F, Fouchard M, Knebelmann B et al. Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective. Kidney International 2018; 93 (3): 716-726. doi: 10.1016/j.kint.2017.08.016